A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Aug 29

PMID 39204078

Authors

Nathaniel W Rolfe

Nicholas B Dadario

Peter Canoll

Jeffrey N Bruce

Affiliations

Soon will be listed here.

Abstract

Glioblastoma remains a devastating disease with a bleak prognosis despite continued research and numerous clinical trials. Convection-enhanced delivery offers researchers and clinicians a platform to bypass the blood-brain barrier and administer drugs directly to the brain parenchyma. While not without significant technological challenges, convection-enhanced delivery theoretically allows for a wide range of therapeutic agents to be delivered to the tumoral space while preventing systemic toxicities. This article provides a comprehensive review of the antitumor agents studied in clinical trials of convection-enhanced delivery to treat adult high-grade gliomas. Agents are grouped by classes, and preclinical evidence for these agents is summarized, as is a brief description of their mechanism of action. The strengths and weaknesses of each clinical trial are also outlined. By doing so, the difficulty of untangling the efficacy of a drug from the technological challenges of convection-enhanced delivery is highlighted. Finally, this article provides a focused review of some therapeutics that might stand to benefit from future clinical trials for glioblastoma using convection-enhanced delivery.

Citing Articles

Nanotherapy of Glioblastoma-Where Hope Grows.

Grzegorzewski J, Michalak M, Woloszczuk M, Bulicz M, Majchrzak-Celinska A Int J Mol Sci. 2025; 26(5).

PMID: 40076445 PMC: 11898975. DOI: 10.3390/ijms26051814.

Unveiling the Inflammatory Landscape of Recurrent Glioblastoma through Histological-Based Assessments.

Dadario N, Boyett D, Teasley D, Chabot P, Winans N, Argenziano M Cancers (Basel). 2024; 16(19).

PMID: 39409905 PMC: 11476027. DOI: 10.3390/cancers16193283.

References

Culver K, Ram Z, Wallbridge S, Ishii H, Oldfield E, Blaese R . In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992; 256(5063):1550-2. DOI: 10.1126/science.1317968. View

Johnson V, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield E . Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg. 1989; 70(2):240-8. DOI: 10.3171/jns.1989.70.2.0240. View

Weaver M, Laske D . Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003; 65(1):3-13. DOI: 10.1023/a:1026246500788. View

Ram Z, Culver K, Oshiro E, Viola J, DeVroom H, Otto E . Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997; 3(12):1354-61. DOI: 10.1038/nm1297-1354. View

Willmon C, Krabbenhoft E, Black M . A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Ther. 2006; 13(17):1309-12. DOI: 10.1038/sj.gt.3302794. View

Nayak L, de Groot J, Wefel J, Cloughesy T, Lieberman F, Chang S . Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017; 132(1):181-188. PMC: 5588922. DOI: 10.1007/s11060-016-2357-9. View

Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A . Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides. 2007; 17(2):201-12. DOI: 10.1089/oli.2006.0053. View

Esteller M, Hamilton S, Burger P, Baylin S, Herman J . Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59(4):793-7. View

Morrison P, Laske D, Bobo H, Oldfield E, Dedrick R . High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994; 266(1 Pt 2):R292-305. DOI: 10.1152/ajpregu.1994.266.1.R292. View

10.

Tanner P, Holtmannspotter M, Tonn J, Goldbrunner R . Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery. 2007; 61(4):E880-2. DOI: 10.1227/01.NEU.0000298922.77921.F2. View

11.

Chen R, Zhang M, Zhou Y, Guo W, Yi M, Zhang Z . The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res. 2020; 39(1):138. PMC: 7368699. DOI: 10.1186/s13046-020-01643-6. View

12.

Brock C, Newlands E, Wedge S, Bower M, Evans H, Colquhoun I . Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58(19):4363-7. View

13.

Schlingensiepen K, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B . Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2005; 17(1-2):129-39. DOI: 10.1016/j.cytogfr.2005.09.002. View

14.

Chinnaiyan P, Won M, Wen P, Rojiani A, Werner-Wasik M, Shih H . A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol. 2017; 20(5):666-673. PMC: 5892159. DOI: 10.1093/neuonc/nox209. View

15.

Pommier Y, Nussenzweig A, Takeda S, Austin C . Human topoisomerases and their roles in genome stability and organization. Nat Rev Mol Cell Biol. 2022; 23(6):407-427. PMC: 8883456. DOI: 10.1038/s41580-022-00452-3. View

16.

Heiss J, Jamshidi A, Shah S, Martin S, Wolters P, Argersinger D . Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma. J Neurosurg Pediatr. 2018; 23(3):333-342. PMC: 7266009. DOI: 10.3171/2018.9.PEDS17225. View

17.

Joshi B, Leland P, Asher A, Prayson R, Varricchio F, Puri R . In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res. 2001; 61(22):8058-61. View

18.

Cohen S, Lippard S . Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001; 67:93-130. DOI: 10.1016/s0079-6603(01)67026-0. View

19.

Pitz M, Desai A, Grossman S, Blakeley J . Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol. 2011; 104(3):629-38. PMC: 4020433. DOI: 10.1007/s11060-011-0564-y. View

20.

Sperring C, Argenziano M, Savage W, Teasley D, Upadhyayula P, Winans N . Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma. Neurooncol Adv. 2023; 5(1):vdad044. PMC: 10195574. DOI: 10.1093/noajnl/vdad044. View